TY  - JOUR
T1  - INVESTIGATION OF METHYLATION AND EXPRESSION STATUS OF PAX1 GENE VIA EPIGENOMIC PROFILING IN ORAL MALIGNANT LESIONS
TT  - INVESTIGATION OF METHYLATION AND EXPRESSION STATUS OF PAX1 GENE VIA EPIGENOMIC PROFILING IN ORAL MALIGNANT LESIONS
AU  - Oztan, Arda
AU  - Ak, Gülsüm
AU  - Ulusan, Murat
AU  - Demokan, Semra
PY  - 2022
DA  - August
DO  - 10.26650/JARHS2021-1142683
JF  - Journal of Advanced Research in Health Sciences
JO  - SABİAD
PB  - Istanbul University
WT  - DergiPark
SN  - 2651-4060
SP  - 57
EP  - 57
VL  - 5
IS  - S-1
LA  - en
AB  - Introduction: Our previously study (TUBITAK-SBAG-114S497) showed hypermethylation of the PAX1 gene in Turkish oral squamous cell carcinoma (OSCC) patients via methylation-array results. In this study, we aimed to validate its potential as an epigenetic biomarker for OSCC by analyzing the methylation status and the changes in methylation-related gene expression of the PAX1 gene in Turkish OSCC patient and healthy groups. Material and Methods: Expression and methylation levels of PAX1 gene were analyzed by Quantitative Real Time-PCR and Quantitative Methylation Specific PCR methods respectively, in tissues and body-fluid samples of 30 OSCC patients and 30 healthy individuals. Results: The methylation rates of the PAX1 gene in matched-normal tissue, tumors, serum and saliva samples of OSCC patients were 50%, 73%, 40%, and 66%, respectively. The methylation rates of the PAX1 gene in normal mucosa, serum and saliva samples of healthy individuals were found to be 6%, 0 and 10%, respectively. In the malignant group, 59% patients in whom methylation was observed in the promoter region of the PAX1 gene in the tumor tissue was found to have decreased expression levels in the tumor tissues compared to the matched-normal tissues.Conclusion: DNA hypermethylation of PAX1 gene may play a role in oral carcinogenesis and may be used as an epigenetic biomarker.
KW  - OSCC
KW  - hypermethylation
KW  - epigenetic biomarker
KW  - PAX1
N2  - Introduction: Our previously study (TUBITAK-SBAG-114S497) showed hypermethylation of the PAX1 gene in Turkish oral squamous cell carcinoma (OSCC)patients via methylation-array results. In this study, we aimed to validate its potential as an epigenetic biomarker for OSCC by analyzing the methylationstatus and the changes in methylation-related gene expression of the PAX1 gene in Turkish OSCC patient and healthy groups.Material and Methods: Expression and methylation levels of PAX1 gene were analyzed by Quantitative Real Time-PCR and Quantitative MethylationSpecific PCR methods respectively, in tissues and body-fluid samples of 30 OSCC patients and 30 healthy individuals.Results: The methylation rates of the PAX1 gene in matched-normal tissue, tumors, serum and saliva samples of OSCC patients were 50%, 73%, 40%, and66%, respectively. The methylation rates of the PAX1 gene in normal mucosa, serum and saliva samples of healthy individuals were found to be 6%, 0 and10%, respectively. In the malignant group, 59% patients in whom methylation was observed in the promoter region of the PAX1 gene in the tumor tissuewas found to have decreased expression levels in the tumor tissues compared to the matched-normal tissues.Conclusion: DNA hypermethylation of PAX1 gene may play a role in oral carcinogenesis and may be used as an epigenetic biomarker.
CR  - Dela Cruz CS, Tanoue LT, Matthay RA. Lung cancer: epidemiology, etiology, and prevention. Clin Chest Med. 2011;32(4):605-44.
UR  - https://doi.org/10.26650/JARHS2021-1142683
L1  - https://dergipark.org.tr/en/download/article-file/2533923
ER  -